Introduction: FRONTIER (NCT02315443) and ESCAPE-NA1 (NCT02930018) are two pivotal trials investigating the safety and efficacy of the neuroprotectant NA-1 in acute ischemic stroke (AIS). NA-1 administration is weight-based (2.6mg/Kg), requiring the rapid estimation of body weight by paramedics in the field (FRONTIER) and by hospital staff upon ED arrival (ESCAPE-NA1). Alteplase, which is administered after hospital arrival, also requires weight-based dosing. Here we evaluated the accuracy of the body weight estimated by paramedics and by hospital staff prior to administering study drug (NA-1 or placebo) as compared to the actual subject weight collected using in-hospital scales during the subsequent in-hospital stay. Methodology: In both these studies, FRONTIER and ESCAPE-NA1, paramedics in the field and Hospital staff will be determining weight by first asking the subject, second asking a family member or third by estimation. Subsequently, in each trial, in-hospital scales are used during the subject’s admission to measure body weight accurately. The subject’s actual weight will be measured in hospital using standard hospital scales (i.e., stand up or in-bed scales if the subject is not ambulatory), as soon as possible, but within five days. Data were obtained from the trial database. Results: As of August 1 st 2018, 264 subjects were enrolled in FRONTIER of which 206 had all body weight data available, and 444 subjects were enrolled in ESCAPE-NA1 of which 218 had all body weight data available. As compared with in-hospital scales, paramedics over estimated patient weight by an average of 2.57 kg (SD = 6.94 P< 0.001). In-hospital staff under estimated patient weight by an average of 1.82kg (SD = 8.93 P=0.003). The difference is statistically significant but not clinically meaningful. Overall, the weight estimated by paramedics and by hospital staff was 93% accurate, when compared to the actual weight collected. Conclusion: Both paramedics and hospital staff were mostly accurate when estimating patient weight in the acute care settings of FRONTIER and ESCAPE-NA1. This suggests that when time is of the essence, weight may be estimated effectively for the purpose of administering stroke drugs.
and eclampsia have an immunogenetic basis which, as Dr Ikedife suggests, is the reverse of rhesus disease-exposure to the relevant antigen being protective rather than the reverse. If this becomes established then the way is open to devise prophylactic immunotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.